Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta‐analysis of randomized clinical trials
Pooled result · Change in HbA1cResult — go to the resultMD −1.27 95% CI −1.49 to −1.0Authors' conclusion
Tirzepatide, particularly at higher doses, demonstrates superior efficacy in lowering HbA1c and reducing hypoglycaemia risk compared with weekly insulin. However, its use is also associated with a higher incidence of AEs and treatment discontinuation.
Study context
- Population
- T2D
- Comparison
- Once-weekly tirzepatide vs once-weekly insulin
- Outcome
- Change in HbA1c
Pooled result
As reported in the abstract
MD
−1.27
95% CI −1.49 to −1.0
Tirzepatide 15 mgvs Weekly insulin
MD −1.27 (95% CI −1.49 to −1.0)
Further pooled results
| Outcome | MD (95% CI) | |
|---|---|---|
| Change in FPGTirzepatide 15 mgvs Weekly insulinRanked highest | −0.70 (−1.05 to −0.34) | |
| Body weightTirzepatide 15 mgvs Weekly insulinMost pronounced effect | −12.13 (−13.98 to −10.27) | |
| −20−10010Difference (linear scale) |
Change in fasting plasma glucose (FPG)
- Tirzepatide 15 mg ranked highest, followed by tirzepatide 10 mg and 5 mg
Body weight
- Tirzepatide led to substantial weight loss
Safety
- Higher incidence of adverse events (AEs) and treatment discontinuation with tirzepatide, particularly at higher doses
Original publication
Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta‐analysis of randomized clinical trials. Diabetes Obes Metab. Published 25 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →